MC
AKTS

Merck & Co’s Aktis Oncology AKTS Stock Holding History

Merck & Co’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.7M Hold
952,844
– – 5.83% 4
2026
Q1 		$17M Buy
+952,844
New +$18.5M 4.88% 6

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Merck & Co's AKTS Position: Q2 2026 in Review

Merck & Co held its Aktis Oncology (AKTS) position steady in Q2 2026 at 952,844 shares worth $30.7M. The position accounts for 5.83% of the portfolio, ranked #4.

Merck & Co first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Merck & Co held 952,844 shares of Aktis Oncology worth $30.7M as of Q2 2026.
  • Merck & Co left its Aktis Oncology share count unchanged in Q2 2026.
  • Aktis Oncology made up 5.83% of Merck & Co's portfolio in Q2 2026, its #4 holding.
  • Merck & Co first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.